94 related articles for article (PubMed ID: 26849668)
1. Cell Death Induction by the Indirubin Derivative 7BIO and the BH3 Mimetic Drugs ABT-737 and GX15-070 in Medullary Thyroid Carcinoma Cells.
Broecker-Preuss M; Becher-Boveleth N; Mann K
Exp Clin Endocrinol Diabetes; 2016 May; 124(5):324-30. PubMed ID: 26849668
[TBL] [Abstract][Full Text] [Related]
2. Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells.
Broecker-Preuss M; Viehof J; Jastrow H; Becher-Boveleth N; Fuhrer D; Mann K
J Exp Clin Cancer Res; 2015 Jul; 34(1):69. PubMed ID: 26198850
[TBL] [Abstract][Full Text] [Related]
3. Induction of atypical cell death in thyroid carcinoma cells by the indirubin derivative 7-bromoindirubin-3'-oxime (7BIO).
Broecker-Preuss M; Becher-Boveleth N; Gall S; Rehmann K; Schenke S; Mann K
Cancer Cell Int; 2015; 15():97. PubMed ID: 26464561
[TBL] [Abstract][Full Text] [Related]
4. The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells.
Broecker-Preuss M; Becher-Boveleth N; Müller S; Mann K
Cancer Cell Int; 2016; 16():27. PubMed ID: 27042160
[TBL] [Abstract][Full Text] [Related]
5. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
6. BH3 mimetics suppress CXCL12 expression in human malignant peripheral nerve sheath tumor cells.
Graham CD; Kaza N; Pruitt HC; Gibson LM; Klocke BJ; Shevde LA; Carroll SL; Roth KA
Oncotarget; 2017 Jan; 8(5):8670-8678. PubMed ID: 28055968
[TBL] [Abstract][Full Text] [Related]
7. Comparison of in vitro antileukemic activity of obatoclax and ABT-737.
Opydo-Chanek M; Mazur L
Tumour Biol; 2016 Aug; 37(8):10839-49. PubMed ID: 26880588
[TBL] [Abstract][Full Text] [Related]
8. Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells.
Hollevoet K; Antignani A; Fitzgerald DJ; Pastan I
J Immunother; 2014 Jan; 37(1):8-15. PubMed ID: 24316551
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA.
Keuling AM; Andrew SE; Tron VA
Pigment Cell Melanoma Res; 2010 Jun; 23(3):430-40. PubMed ID: 20337986
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
Abed MN; Abdullah MI; Richardson A
J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
[TBL] [Abstract][Full Text] [Related]
12. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
13. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
14. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.
Allaman-Pillet N; Oberson A; Munier F; Schorderet DF
Ophthalmic Genet; 2013; 34(1-2):1-13. PubMed ID: 21955141
[TBL] [Abstract][Full Text] [Related]
15. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
[TBL] [Abstract][Full Text] [Related]
16. The BH3 mimetic ABT-737 induces cancer cell senescence.
Song JH; Kandasamy K; Zemskova M; Lin YW; Kraft AS
Cancer Res; 2011 Jan; 71(2):506-15. PubMed ID: 21084274
[TBL] [Abstract][Full Text] [Related]
17. The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.
Lieber J; Armeanu-Ebinger S; Fuchs J
Int J Mol Sci; 2015 Feb; 16(2):4190-208. PubMed ID: 25690034
[TBL] [Abstract][Full Text] [Related]
18. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
[TBL] [Abstract][Full Text] [Related]
19. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death.
Ribas J; Bettayeb K; Ferandin Y; Knockaert M; Garrofé-Ochoa X; Totzke F; Schächtele C; Mester J; Polychronopoulos P; Magiatis P; Skaltsounis AL; Boix J; Meijer L
Oncogene; 2006 Oct; 25(47):6304-18. PubMed ID: 16702956
[TBL] [Abstract][Full Text] [Related]
20. BH3 mimetics reduce adhesion and migration of hepatoblastoma and hepatocellular carcinoma cells.
Vogt F; Lieber J; Dewerth A; Hoh A; Fuchs J; Armeanu-Ebinger S
Exp Cell Res; 2013 Jun; 319(10):1443-50. PubMed ID: 23416067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
